Mesoblast Ltd. products

MPC-25-IC is Mesoblast’s Phase 2 product candidate for the treatment of acute myocardial infarction. This is the first clinical study to evaluate an allogeneic cellular therapy delivered by intracoronary infusion in patients who have suffered an acute myocardial infarction.

Revascor is a Phase 3 product candidate being developed as a treatment for both advanced and end-stage chronic heart failure (CHF).

Remestemcel-L is being developed for inflammatory diseases in children and adults including the treatment of acute graft versus host disease (aGVHD), a potentially life-threatening complication of an allogeneic bone marrow transplant (BMT). Currently, there are no products currently approved in the United States for treatment of steroid-refractory aGVHD in children under 12, and off-label options have demonstrated mixed efficacy with high toxicity.

Mesoblast’s proprietary mesenchymal lineage adult stem cells (MLCs) are found in multiple tissues where they play vital roles in maintaining tissue health.

MPC-300-IV is being developed for the treatment of diabetic complications, including diabetic kidney disease known as diabetic nephropathy.